Blood test guides cancer treatment: doctors try custom doses to boost survival, cut side effects
NCT ID NCT07425054
Summary
This study is testing a personalized approach to standard chemoradiation therapy for people with locally-advanced anal cancer. Doctors will use a blood test that detects tumor DNA to see how well the cancer is responding during treatment. Based on the test results, they will adjust the chemo-radiation dose up or down, aiming to improve survival while reducing side effects. Some participants whose cancer responds poorly may also receive an immunotherapy drug called retifanlimab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.